Author:
Barrington P.,Chien J. Y.,Tibaldi F.,Showalter H. D. H.,Schneck K.,Ellis B.
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy;Journal of Medical Economics;2024-07-04
2. The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months;Diabetes, Obesity and Metabolism;2023-09-15
3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial;The Lancet;2022-11
4. Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys;European Journal of Pharmaceutical Sciences;2022-08
5. Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study;Advances in Therapy;2021-11-17